8YW8 image
Deposition Date 2024-03-30
Release Date 2025-03-12
Last Version Date 2025-05-14
Entry Detail
PDB ID:
8YW8
Title:
Cryo-EM structure of human mitochondrial pyruvate carrier in complex with the inhibitor UK5099
Biological Source:
Source Organism:
Host Organism:
Method Details:
Experimental Method:
Resolution:
3.17 Å
Aggregation State:
PARTICLE
Reconstruction Method:
SINGLE PARTICLE
Macromolecular Entities
Polymer Type:polypeptide(L)
Molecule:Mitochondrial pyruvate carrier 1
Gene (Uniprot):MPC1
Chain IDs:C (auth: A)
Chain Length:120
Number of Molecules:1
Biological Source:Homo sapiens
Polymer Type:polypeptide(L)
Molecule:Mitochondrial pyruvate carrier 2
Gene (Uniprot):MPC2
Chain IDs:A (auth: B)
Chain Length:151
Number of Molecules:1
Biological Source:Homo sapiens
Polymer Type:polypeptide(L)
Molecule:MPC specific nanobody 1
Chain IDs:B (auth: C)
Chain Length:138
Number of Molecules:1
Biological Source:Escherichia coli BL21(DE3)
Primary Citation
Structures and mechanism of the human mitochondrial pyruvate carrier.
Nature 641 258 265 (2025)
PMID: 40101766 DOI: 10.1038/s41586-025-08873-8

Abstact

Mitochondrial pyruvate carrier (MPC) is a mitochondrial inner membrane protein complex essential for uptake of pyruvate into matrix as the primary carbon source for tricarboxylic acid (TCA) cycle1,2. Here, we report six cryo-EM structures of human MPC in three different states: three structures obtained at different conditions in intermembrane space (IMS)-open state with highest resolution of 3.2 Å, a structure of pyruvate-treated MPC in occluded state at 3.7 Å, and two structures in matrix-facing state bound with the inhibitor UK5099 or an inhibitory nanobody on the matrix side at 3.2 Å and 3.0 Å, respectively. MPC is assigned into a heterodimer consisting of MPC1 and MPC2, with the transmembrane domain adopting pseudo-C2-symmetry. Approximate rigid body movements occur between the IMS-open state and the occluded state, while structural changes primarily on the matrix side facilitate the transition between the occluded state and the matrix-facing state, revealing the alternating access mechanism during pyruvate transport. In the UK5099-bound structure, the inhibitor fits well and interacts extensively with a pocket that opens to the matrix side. Our findings provide important insights into the mechanisms underlying MPC-mediated substrate transport, and the recognition and inhibition by UK5099, which will facilitate future drug development targeting MPC.

Legend

Protein

Chemical

Disease

Primary Citation of related structures